An arrayed CRISPR screen reveals Myc depletion to increase productivity of difficult-to-express complex antibodies in CHO cells

• Published in: Synthetic biology (Oxford University Press) 2022, Vol.7 (1), p.ysac026-ysac026
• Main Authors: Bauer, Niels, Oswald, Benedikt, Eiche, Maximilian, Schiller, Lisa, Langguth, Emma, Schantz, Christian, Osterlehner, Andrea, Shen, Amy, Misaghi, Shahram, Stingele, Julian, Ausländer, Simon
• Format: Article
• Language: English
• ISSN: 2397-7000; 2397-7000
• DOI: 10.1093/synbio/ysac026

Abstract Complex therapeutic antibody formats, such as bispecifics (bsAbs) or cytokine fusions, may provide new treatment options in diverse disease areas. However, the manufacturing yield of these complex antibody formats in Chinese Hamster Ovary (CHO) cells is lower than monoclonal antibodies due to challenges in expression levels and potential formation of side products. To overcome these limitations, we performed a clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9)-based knockout (KO) arrayed screening of 187 target genes in two CHO clones expressing two different complex antibody formats in a production-mimicking set-up. Our findings revealed that Myc depletion drastically increased product expression (>40%) by enhancing cell-specific productivity. The Myc-depleted cells displayed decreased cell densities together with substantially higher product titers in industrially-relevant bioprocesses using ambr15 and ambr250 bioreactors. Similar effects were observed across multiple different clones, each expressing a distinct complex antibody format. Our findings reinforce the mutually exclusive relationship between growth and production phenotypes and provide a targeted cell engineering approach to impact productivity without impairing product quality. We anticipate that CRISPR/Cas9-based CHO host cell engineering will transform our ability to increase manufacturing yield of high-value complex biotherapeutics. Graphical Abstract